Arabic Arabic English English French French German German
dark

I-Mab Announces First Patient Dosed in China Phase 2 Clinical Trial of Efineptakin Alfa in Combination with Pembrolizumab in Advanced Solid Tumors

I-Mab today announced that the first patient had been dosed in its China phase 2 study (NCT05145907) of efineptakin alfa. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

The unexpected benefits of fat in type 2 diabetes

Next Post

Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC

Related Posts
Total
0
Share